Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1254

Sort by

Sort Order Select

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler, Denis Rybin, Andrew L. Frelinger, III, Alan D. Michelson, Ke Liu, Xiufeng Gao, Jennell White, Ahmar U. Zaidi, Robert J. Charnigo, Michael U. Callaghan

Blood (2021) 137 (15): 2010–2020.

https://doi.org/10.1182/blood.2020006020

Published: 2021

Includes: Supplemental data

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Annelies J. Van Vuren, MD, Laurel Mendelsohn, BS, Richard van Wijk, PhD, Caterina P. Minniti, MD, John Baird, MD, Gregory J Kato, MD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 2274.

https://doi.org/10.1182/blood-2019-124048

Published: 2019

Journal Articles

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Marisol Betensky, MDMPH, Ernest Amankwah, PhD, Stephanie Brandal, Allen Everett, MD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 2424.

https://doi.org/10.1182/blood-2019-131821

Published: 2019

Journal Articles

Protein Cysteine Sulfenylation By CD36-Dependent Reactive Oxygen Species Signaling Promotes Platelet Activation

Moua Yang, PhD, Calvin Harberg, Wenjing Chen, Sarah L. Wynia-Smith, PhD, Kate S. Carroll, PhD, Jacek Zielonka, PhD, Roy L. Silverstein, MD, Brian C. Smith, PhD

Blood (2019) 134 (Supplement_1): 2338.

https://doi.org/10.1182/blood-2019-122465

Published: 2019

Journal Articles

Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients

Emily Bontekoe, Matthew T. Rondina, MD, Debra Hoppensteadt, PhD, Elizabeth Middleton, MD, Antoinette Blair, Fakiha Siddiqui, Divya Joshi, Alyssandra Abrenica, Iman Darwish, Maryanne Amour, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 2401.

https://doi.org/10.1182/blood-2019-130420

Published: 2019

Journal Articles

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Ryan C Henrici, PhD BS, Casey Sautter, MDMS, Robert Opoka, MMED, Ruth Namazzi, MD, Gregory S Park, Dibyadyuti John, PhD, Andrea L Conroy, PhD, Russell E. Ware, MD PhD, Chandy C. John, MDMS

Blood (2019) 134 (Supplement_1): 2283.

https://doi.org/10.1182/blood-2019-129566

Published: 2019

Journal Articles

Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients

Iman Darwish, Yevgeniy Brailovsky, DO, Amir Darki, MD MSc, Debra Hoppensteadt, PhD, Brett Slajus, Emily Bontekoe, Frank De Stefano, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 2408.

https://doi.org/10.1182/blood-2019-126876

Published: 2019

Journal Articles

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Blood (2019) 134 (Supplement_1): 2375.

https://doi.org/10.1182/blood-2019-129200

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Blood (2019) 134 (Supplement_1): 1416.

https://doi.org/10.1182/blood-2019-127082

Published: 2019

Journal Articles

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Odelia Amit, MD, Yael Bar-On, MD, Galit Perets, MD, Lena Atlas, Liat Shargian, MD, Moshe Yeshurun, MD, Bruria Yachini, RN, Chen Karni, RN, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 2018.

https://doi.org/10.1182/blood-2019-126999

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Taking aim at IDH in fitter patients with AML

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Protein Cysteine Sulfenylation By CD36-Dependent Reactive Oxygen Species Signaling Promotes Platelet Activation

Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only